Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Servier
University of Iowa
IGM Biosciences, Inc.
TopAlliance Biosciences
Fred Hutchinson Cancer Center
University of Miami
Rutgers, The State University of New Jersey
Valerio Therapeutics
Valerio Therapeutics
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Case Comprehensive Cancer Center